Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia (APL) – Treatment Options

Introduction
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML-M3), caused by the t(15;17) translocation, leading to the PML-RARA fusion gene. It is characterized by an accumulation of abnormal promyelocytes and a high risk of life-threatening disseminated intravascular coagulation (DIC). With modern targeted therapy, APL has one of the best cure rates among leukemias. Treatment involves rapid initiation of differentiating agents, chemotherapy or arsenic trioxide, and aggressive supportive care.

1. Emergency and Supportive Management

• Immediate initiation of all-trans retinoic acid (ATRA):

  • Start as soon as APL is suspected (before genetic confirmation) to reduce early mortality from coagulopathy.

• Coagulopathy management:

  • Platelet transfusions to maintain platelets >30,000–50,000/µL.

  • Fresh frozen plasma or cryoprecipitate to keep fibrinogen >150 mg/dL.

  • Monitor coagulation profile closely.

• Infection control:

  • Broad-spectrum antibiotics for febrile neutropenia.

• Tumor lysis prevention:

  • IV fluids, allopurinol, or rasburicase.

2. Induction Therapy (Remission Induction)

• ATRA (all-trans retinoic acid):

  • Promotes differentiation of promyelocytes into mature granulocytes.

• Arsenic trioxide (ATO):

  • Highly effective; induces differentiation and apoptosis.

• Risk-adapted addition of anthracyclines (idarubicin, daunorubicin):

  • Used in high-risk patients (WBC >10,000/µL).

• Goal: Achieve complete remission with normalization of blood counts and disappearance of abnormal promyelocytes.

3. Consolidation Therapy

• ATRA + ATO (± anthracyclines):

  • Multiple cycles given after remission induction.

• High cure rates (>80–90%) achieved with ATRA + ATO combinations, even without chemotherapy in low-risk patients.

4. Maintenance Therapy

• ATRA ± low-dose chemotherapy (6-mercaptopurine, methotrexate):

  • Historically used for 1–2 years, though less commonly required with modern ATRA + ATO regimens.

5. Targeted/Novel Therapies

• ATO-based regimens: Increasingly used frontline, especially in standard-risk APL, often avoiding chemotherapy.

• Stem cell transplantation (HSCT): Reserved for relapsed/refractory disease, not standard for patients in first remission.

6. Monitoring and Complication Management

• Differentiation syndrome (DS):

  • Life-threatening complication of ATRA/ATO therapy (fever, weight gain, pulmonary infiltrates, pleural/pericardial effusion).

  • Treated with dexamethasone (10 mg IV twice daily) and temporary discontinuation of differentiating agents if severe.

• QT prolongation with ATO:

  • ECG monitoring and electrolyte correction required.

• Minimal residual disease (MRD):

  • Molecular monitoring with RT-PCR for PML-RARA transcript to detect relapse early.

7. Multidisciplinary Care

• Hematologists/oncologists: For chemotherapy, targeted therapy, and monitoring.

• Transfusion specialists: For managing coagulopathy and blood product support.

• Intensivists: For severe cases with DIC, differentiation syndrome, or multi-organ involvement.

• Cardiologists: For QT monitoring during arsenic therapy.